Publicaciones en colaboración con investigadores/as de Hospital Universitario de la Princesa (26)

2024

  1. Cardiovascular risk assessment: Missing albuminuria contributing to gender inequality

    Nefrologia

  2. Genetic study in young patients with chronic kidney disease stage G5 from unknown etiology. The GENSEN study design

    Nefrologia

2023

  1. Humoral response after the fourth dose of the SARS-CoV-2 vaccine in the CKD spectrum: a prespecified analysis of the SENCOVAC study

    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, Vol. 38, Núm. 4, pp. 969-981

  2. Lessons from SENCOVAC: A prospective study evaluating the response to SARS-CoV-2 vaccination in the CKD spectrum

    Nefrologia

  3. Lessons from SENCOVAC: A prospective study evaluating the response to SARS-CoV-2 vaccination in the CKD spectrum

    Nefrologia, Vol. 43, Núm. 6, pp. 676-687

  4. Reticulocyte hemoglobin content and iron therapy in chronic kidney disease: Reply of the Anemia group of the Spanish Society of Nephrology

    Nefrologia

  5. Reticulocyte hemoglobin content and iron therapy in chronic kidney disease: Response of the Anemia group of the Spanish Society of Nephrology

    Nefrologia

  6. The Spanish Scientific Societies before the ESC 2021 guidelines on vascular disease prevention: Generalizing the measurement of albuminuria to identify vascular risk and prevent vascular disease

    Nefrologia, Vol. 43, Núm. 2, pp. 245-250

  7. Update of the prevention and isolation measure recommendations against SARS-COV-2 in dialysis units of Spain: A position paper of the Spanish Society of Nephrology Council

    Nefrologia

2022

  1. Actualización de las recomendaciones de medidas de prevención y aislamiento frente al SARS-CoV-2 en las unidades de diálisis: un posicionamiento de la Sociedad Española de Nefrología

    Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia, Vol. 42, Núm. 6, pp. 714-721

  2. Anti-Spike antibodies 3 months after SARS-CoV-2 mRNA vaccine booster dose in patients on hemodialysis: the prospective SENCOVAC study

    Clinical Kidney Journal, Vol. 15, Núm. 10, pp. 1856-1864

  3. Humoral Response to Third Dose of SARS-CoV-2 Vaccines in the CKD Spectrum

    Clinical journal of the American Society of Nephrology : CJASN

  4. Long-Term Dynamic Humoral Response to SARS-CoV-2 mRNA Vaccines in Patients on Peritoneal Dialysis

    Vaccines, Vol. 10, Núm. 10

  5. Loss of humoral response 3 months after SARS-CoV-2 vaccination in the CKD spectrum: the multicentric SENCOVAC study

    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, Vol. 37, Núm. 5, pp. 994-999

  6. SARS-CoV-2 Infection Evolution Among Nephrologists During the Pandemic: Clinical Features and Impact of Vaccination

    Kidney International Reports, Vol. 7, Núm. 7, pp. 1686-1689

  7. Safety and immediate humoral response of COVID-19 vaccines in chronic kidney disease patients: the SENCOVAC study

    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, Vol. 37, Núm. 10, pp. 1868-1878

2021

  1. COVID-19 vaccination among Spanish nephrologists: Acceptance and side effects

    Journal of Healthcare Quality Research, Vol. 36, Núm. 6, pp. 363-369

  2. Ferroterapia en el manejo de la anemia en la enfermedad renal crónica no en diálisis: perspectiva del grupo de anemia de la S.E.N

    Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia, Vol. 41, Núm. 2, pp. 123-136

  3. Position statement of the Spanish Society of Nephrology on the SARS-CoV-2 vaccines

    Nefrologia, Vol. 41, Núm. 4, pp. 412-416

2018

  1. Aspirin for Primary Prevention of Cardiovascular Disease and Renal Disease Progression in Chronic Kidney Disease Patients: a Multicenter Randomized Clinical Trial (AASER Study)

    Cardiovascular Drugs and Therapy, Vol. 32, Núm. 3, pp. 255-263